News about Global Pharma

Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.

Global Pharma | 19/12/2024 | By Aishwarya |  546

MTPA Signs Deal with Dewpoint to Advance Small Molecule Condensate Modulator

The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.

Global Pharma | 19/12/2024 | By Aishwarya |  311

Noema Pharma Closes its Series B Financing Round with USD 147 Million Capital Funding

The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.

Global Pharma | 18/12/2024 | By Aishwarya |  611

Lilly and EVA Pharma Secure Approval to Distribute Locally Manufactured Insulin in Egypt

Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.

Global Pharma | 18/12/2024 | By Aishwarya |  877

AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline

AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.

Global Pharma | 18/12/2024 | By Aishwarya |  751

ENEA-Tech Invests EUR 6 Million in BetaGlue Therapeutics

This EUR 6 million investment from ENEA-Tech follows the EUR 8 million equity financing round and the EUR 10 million EIC Accelerator Award announced in June of this year.

Global Pharma | 17/12/2024 | By Aishwarya |  355

VectorY Welcomes Jim Scibetta as New CEO

Scibetta brings more than 20 years of executive leadership experience, having built earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies.

Global Pharma | 17/12/2024 | By Aishwarya |  391

CPHI Milan Records 59,000 Visitors from Pharma Industry

The event’s success is widely used as a proxy for overall growth in global pharma in the year ahead, with attendance up 9 percent on 2023 and a remarkable 45 percent over the last two years.

Global Pharma | 17/12/2024 | By Aishwarya |  521

Gland Pharma Gets FDA Approval for Phytonadione Injectable Emulsion

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.

Global Pharma | 16/12/2024 | By Aishwarya |  541

Neurocrine Biosciences Secures FDA Approval of CRENESSITY

CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.

Global Pharma | 16/12/2024 | By Aishwarya |  203